{
    "nct_id": "NCT06246110",
    "official_title": "A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer",
    "inclusion_criteria": "1. be â‰¥ 18 years of age on the day of signing of informed consent.\n2. confirmed Stage 4 NSCLC (squamous or non-squamous) and be considered for standard of care.\n3. have confirmation that mutation-directed therapy is not indicated (documentation of absence of tumor activating mutations/fusions that are approved for first line therapy).\n4. have at least 1 lesion with measurable disease at Baseline according to RECIST 1.1 as determined by the local site Investigator/radiology assessment.\n5. have not received prior systemic treatment for advanced/metastatic NSCLC.\n6. have an ECOG Performance Status of 0 to 1.\n7. have adequate organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. does not have predominantly squamous cell or non-squamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the participant is ineligible.\n2. is currently participating in or has participated in a study of an investigational agent and received investigational therapy within 4 weeks or 5 half-lives (whichever is shorter) of administration of EIK1001.\n3. prior to the first dose of EIK1001, has received prior systemic therapy for metastatic disease, or had major surgery (< 3 weeks prior to the first dose).\n4. has completed palliative radiotherapy within 7 days of the first dose of study drug administration.\n5. has a known history of prior malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years.\n6. has an active infection requiring therapy.",
    "miscellaneous_criteria": ""
}